April 26, 2017 8:57pm

 

The sector wobbled weakness to neutrality to strength

 

Yet, bets using options are on the rise to record highs

 

What are investors expecting – a longer trend?

 

Pre-open indications: 4 hits and 3 miss - strengthening a cell therapy portfolio

My offer - ensuing weakness!

 

The truth is harsh, but reality is what it is …

 

I answer one question, in which company should investors commit and keep their money

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “The sector is overbought, but there are no sell signals – yet! The sector is overbought, but there are no sell signals – yet!”

  • Reiterating, “I’m not backing down as remaining long is dangerous.”

While offering a useful guide what the stem, cell, gene and regenerative therapy i.e. cell therapy sector is writing; minimal news has contributed to a moment, alternative movement within the session.

 

 

What analytics were there on Wednesday day and why it was important in today’s sector outcomes?

One answer … The DOW closed down -0.10% while the NASDAQ closed down -0.00 … adding to what I said yesterday, emotional influence takes its toll, but investors need to be careful of this newest apex!

  • Reiterating, “Q1/17 cell therapy sector results are in the making and spending patterns, cash positions and clinical results will be on parade!”

Today’s highs traveled from a neutral open (uncertainty> to a solid mid-day <an A/DL of 27/13> to an expanded closing <an A/DL of 32/7>; the question continues … of follow-on days of support!

 

The cell therapy sector’s record of three positive closes in a row added to five sessions in six days

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.8 again…

·  As Tuesday traded near 10.8, Monday traded 10.9 – down -25.6% followed by Friday trading near 14.67 after Thursday’s near 14 after Wednesday’s near 14.98;

 

... The iShares Russell 2000 (IWM) indicated a negative -0.17% at the pre-open was and closed UP +0.51%;

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed UP +0.29%

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative  with an A/DL of 16/22 and 5 flats;

  • ​10; 30 am was neutral with an A/DL of 20/20 and 3 flats;

·         The mid-day stayed positive with an A/DL of 27/13 and 3 flat;

·         The close was positive with an A/DL of 32/7 and 4 flats;

 

… Decliners ranged from -0.51% <VTGN> to -3, 73% <MDXG> in 7 equities;

… Gainers ranged from +0.32% <KOOL> to +30.07% <NWBO> in 32 equities;

 

 

Pre-open indications: 4 hits and 3 miss

·         Asterias Biotherapeutics (NYSEMKT: AST) closed up +$0.30 – hit;

·         bluebird bio (BLUE) closed up +$0.90 – hit;

·         Capricor (CAPR) closed flat at $3.23 – hit;

·         Cellectis SA (CLLS) closed up +$0.26 – miss;

·         Juno Therapeutics (JUNO) closed up +$0.15 – hit;

·         Mesoblast (MESO) closed up +$0.04 – miss;

·         Spark Therapeutics (ONCE) closed up +$0.32 – miss;

 

Percentage gainers:

·          

·         MiMedx (MDXG) -3.73Z%,

·         Reneuron (RENE.L) -2.25%,

·         Vericel (VCEL) -1.89%,

·         Pluristem (PSTI) -1.37%,

·         Neuralstem (CUR) -1.21%,

 

 

Percentage losers:

·         Northwest BIO (NWBO) +30.07,

·         Asterias Biotherapeutics (NYSEMKT: AST) +8% following Tuesday’s +10.29% after Monday’s+9.68%,

·         International Stem Cell (ISCO) +7.36%,

·         uniQure (QURE) +5.74%,

·         Adverum (ADVM) +5.66%

 

 

Dollar gainers:

·         Kite Pharma (KITE) +$2.23 following Tuesday’s -$1.68,

·         Bluebird bio (BLUE) +$0.90 following Tuesday’ +$2.10 after Monday’s +$3.25,

·         Mesoblast (MESO) +$0.47,

·         Stemline (STML) +$0.35 following Tuesday’s +$0.35,

·         Spark Therapeutics (ONCE) +$0.32 following Tuesday’s +$2.08 after Monday’s +$2.34,

 

 

Dollar losers:

·         MiMedx (MDXG) -$0.43,

·         Neuralstem (CUR) -$0.06,

·         Vericel (VCEL) -$0.05,

·         ReNeuron (RENE.L) -$0.05 after Tuesday’s -$0.10,

·         Pluristem (PSTI) -$0.02

 

Flats:

·         BioTime (NYSEMKT: BTX),

·         BioLife Solutions (BLFS),

·         Capricor (CAPR),

·         Cytori (CYTX),

 

 

Volume standouts versus 3 month averages:

Low volume, stock climbs

·         Caladrius Biosciences (CLBS)+$0.13,

·         Fibrocell (FCSC) +$0.11,

·         Osiris (OSIR) +$0.06,

·         Brainstorm (BCLI) +$0.05,

·         Stemline (STML) +$0.35,

·         Verastem (VSTM) +$0.10,

·         Sangamo (SGMO) +$0.25,

·          

Higher volume, stock climbs:

·         Mesoblast (MESO) +$0.47,

·         Applied Genetic Technologies (AGTC) +$0.05,

·         Asterias Biosciences (NYSEMKT: AST) +$0.30,

·         Adverum (ADVM) +$0.15,

·         Northwest Bio (NWBO) +0.0445

High volume, stock drops:

·         MiMedx (MDXG) -$0.43,

Low volume, stock drops:

·         Biostage (BSTG) -$0.003

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.